Abstract 397P
Background
Current treatment options for HER2-positive (IHC 3+, or IHC 2+/FISH+) metastatic breast cancer (MBC) at third-line and above have shown limited clinical benefit. There is no recommended HER2-targeting treatment for HER2-low expressing (IHC 2+/FISH-, or IHC 1+) population. Here, we report the efficacy and safety of RC48-ADC in patients with MBC.
Methods
Patients with HER2-positive or HER2-low expressing MBC were eligible and received RC48 2.5 mg/kg every two weeks alone or combined with drugs with different anti-tumor mechanisms, such as immune checkpoint inhibitors (ICIs), tyrosine kinase inhibitors (TKIs) and antiangiogenic compounds. The primary endpoint was the objective response rate (ORR). Secondary endpoints included progression-free survival (PFS), overall survival (OS), disease control rate (DCR) and safety.
Results
76 female MBC patients were enrolled and treated with RC48. 58 patients (76.3%) were HER2-positive and 18 patients (23.7%) were HER2-low expressing. At baseline, 35 patients (46.0%) had liver metastases, 27 patients (35.5%) had brain metastases, and 67 patients (88.1%) had received ≥3 prior chemotherapy regimens. In the overall population, the ORR was 31.6%. The median PFS was 5.7 months. The DCR was 57.9%. In the HER2-positive subgroup, the ORR and mPFS were 34.5% and 6.3 months. In the HER2-low expressing subgroup, the ORR and mPFS were 22.2% and 3.6 months. In addition, the mPFS in the dual drug combination-treated group was longer than that in the single drug treatment group, with mPFS of 7.1 months and 4.6 months, respectively. The most frequently reported adverse events were increased AST (62.4%), increased ALT (61.9%), decreased white blood cell count (42.4%), and fatigue (30.4%), most were grade 1-2 in severity.
Conclusions
RC48-ADC showed consistent efficacy in HER2-positive and HER2-low expressing subgroups. No new safety signals were observed. Coadministration with ICIs, TKIs and antiangiogenic compounds demonstrated substantially enhanced efficacy and could be a future direction of ADC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
349P - The influence of diabetes on taxane-induced neurotoxicity and quality of life in breast cancer patients
Presenter: Erika Cimbro
Session: Poster session 03
350P - Quality of life data on sexual relations in early breast cancer patients
Presenter: María Garrido
Session: Poster session 03
351TiP - EORTC BCG 1984 – NOBLE: Noeoadjuvant olaparib and durvalumab for patients with BRCA-associated triple-negative breast cancer
Presenter: Emanuel Buhrer
Session: Poster session 03
352TiP - Neoadjuvant chemo-immunotherapy plus/minus fasting-like approach in stage II-III triple-negative breast cancer patients: The phase II randomized BREAKFAST-2 trial
Presenter: Claudio Vernieri
Session: Poster session 03
355P - Reduction of anthracycline use with a combined imaging and pathology prediction model in the neoadjuvant I-SPY2 trial
Presenter: Angela DeMichele
Session: Poster session 03
356P - Prognostic value of the residual cancer burden after neoadjuvant chemotherapy for invasive lobular breast cancer: An international pooled cohort study
Presenter: Soumya Gottipati
Session: Poster session 03
357P - Prediction of pathologic response to neoadjuvant chemotherapy (NAC) using diffuse optical breast scanner (DOB-Scan) in patients with locally advanced breast cancer (LABC)
Presenter: Phuong Thao Nguyen
Session: Poster session 03
358P - Major adverse cardiovascular event outcomes of adjuvant taxane + anthracycline versus taxane-based chemotherapy in older adults with triple-negative breast cancer: A SEER-Medicare study
Presenter: Savannah Roy
Session: Poster session 03